{"entity":{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","aka":[],"tldr":"Led ASCENT, the trial that made sacituzumab govitecan the first ADC for triple-negative breast cancer, and the EMERALD trial of elacestrant.","summary":"Aditya Bardia was principal investigator of ASCENT, which showed sacituzumab govitecan nearly doubles survival in pretreated metastatic TNBC, and of EMERALD, which won elacestrant the first oral SERD approval for ESR1-mutant disease. He is a lead investigator on the TROPION-Breast programme and ctDNA-guided studies. His work has defined the TROP2 ADC class in breast cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bardia%20A%5BAuthor%5D%20sacituzumab%20OR%20elacestrant"}],"tags":["breast","adc","trialist"],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["adc","endocrine-therapy","liquid-biopsy"],"targets":["trop2","estrogen-receptor"],"drugs":["sacituzumab-govitecan","datopotamab-deruxtecan","elacestrant"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":["ascent","tropion-breast01","emerald"],"people":[],"bottlenecks":[],"keyPapers":["paper-ascent-nejm-2021","paper-tropion-breast01-jco-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Director of Translational Research Integration, UCLA Jonsson Comprehensive Cancer Center","institutionId":"ucla-jonsson","specialisms":["Antibody-drug conjugates","Triple-negative breast cancer","Oral SERDs","Circulating tumour DNA"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bardia%20A%5BAuthor%5D%20sacituzumab%20OR%20elacestrant"}],"papers":[{"title":"Sacituzumab govitecan in metastatic triple-negative breast cancer (ASCENT)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2028485"},{"title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer (EMERALD)","journal":"JCO","year":2022,"doi":"10.1200/JCO.22.00338"},{"title":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","journal":"Journal of Clinical Oncology","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TROPION-Breast01+datopotamab+deruxtecan+Bardia"}],"orcid":"0000-0003-4885-1157"},"route":"/people/aditya-bardia/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"institution":[{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/"}],"trial":[{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/"},{"id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/"},{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/"}],"paper":[{"id":"paper-ascent-nejm-2021","kind":"paper","name":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","route":"/key-papers/paper-ascent-nejm-2021/"},{"id":"paper-bardia-ascent-trop2-biomarker-ann-oncol-2021","kind":"paper","name":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","route":"/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/"},{"id":"paper-tropion-breast01-china-cohort-esmo-open-2026","kind":"paper","name":"TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer","route":"/key-papers/paper-tropion-breast01-china-cohort-esmo-open-2026/"},{"id":"paper-tropion-breast01-jco-2024","kind":"paper","name":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","route":"/key-papers/paper-tropion-breast01-jco-2024/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}